

12670 High Bluff Drive
San Diego, California 92130
Tel: +1.858.523.5400 Fax: +1.858.523.5450
www.lw.com

LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES

Austin	Moscow
Beijing	Munich
Boston	New York
Brussels	Orange County
Century City	Paris
Chicago	Riyadh
Dubai	San Diego
Düsseldorf	San Francisco
Frankfurt	Seoul
Hamburg	Shanghai
Hong Kong	Silicon Valley
Houston	Singapore
London	Tel Aviv
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

June 17, 2022

VIA EDGAR

Ms. Jane Park
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549

**Re: Connect Biopharma Holdings Limited
Amendment No. 1 to Registration Statement on Form F-3
Filed May 23, 2022
File No. 333-264340**

Dear Ms. Park:

We are in receipt of the Staff's letter dated June 3, 2022 with respect to the above-referenced Registration Statement (the "**Registration Statement**"). We are responding to the Staff's comment on behalf of Connect Biopharma Holdings Limited ("**Connect**" or the "**Company**") as set forth below. Simultaneously with the submission of this letter, the Company is filing via EDGAR Amendment No. 2 to the Registration Statement (the "**Amended Registration Statement**") responding to the Staff's comment and updating the Registration Statement.

The Company's response set forth in this letter is numbered to correspond to the numbered comment in the Staff's letter. All terms used but not defined herein have the meanings assigned to such terms in the Amended Registration Statement. For ease of reference, we have set forth the Staff's comment and the Company's response below.

Amendment No. 1 to Registration Statement on Form F-3 filed May 23, 2022

Our Company, page 3

1. *We acknowledge your revised disclosure in response to prior comment 2 that you and your PRC subsidiaries are not subject to any permission requirements from the CSRC, the CAC or other governmental agency that is required for this offering and that your PRC subsidiaries have obtained all necessary licenses and approvals to conduct your operations in China. Please advise whether you relied on outside PRC counsel as the basis*

LATHAM & WATKINS LLP

for your belief that you are not subject to the review or required to obtain prior approval, and if so, file a consent.

Connect's Response: The Company has revised the disclosure on pages 3, 4, 47, S-11, S-12 and S-49 of the Amended Registration Statement in response to the Staff's comment. Additionally, the Company has filed the consent of its outside PRC counsel, Han Kun Law Offices, as Exhibit 23.3 of the Amended Registration Statement.

LATHAM & WATKINS LLP

Any comments or questions regarding the foregoing should be directed to the undersigned at (858) 523-3959. Thank you in advance for your cooperation in connection with this matter.

Sincerely,

/s/ Michael Sullivan

Michael Sullivan
of LATHAM & WATKINS LLP

cc: Jason Drory, *Securities Exchange Commission*
Jiang Bian, Esq., *Connect Biopharma Holdings Limited*
Cheung Ying (Cathy) Yeung, Esq., *Latham & Watkins LLP*
Alan F. Denenberg, *Davis Polk & Wardwell LLP*
Emily Roberts, *Davis Polk & Wardwell LLP*
Donald K. Lang, *Davis Polk & Wardwell LLP*